Drugs / GFF MDI
GFF MDI
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01980615 | Nov → Dec 2013 | — | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFF MDI | “a glycopyrronium/formoterol fumarate dihydrate co-suspension delivery technology MDI (GFF MDI 14.4/10 μg) in healthy volunteers (18-45 years of age).” PMID 29544728 ↗ Mar 2018 |
| Known as | GFF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01980615 ↗ |
| Known as | glycopyrronium/formoterol fumarate dihydrate co-suspension delivery technology MDI | “a glycopyrronium/formoterol fumarate dihydrate co-suspension delivery technology MDI (GFF MDI 14.4/10 μg) in healthy volunteers (18-45 years of age).” PMID 29544728 ↗ Mar 2018 |
| Known as | PT003 | “Inhaled GFF (PT003)” NCT01980615 ↗ |
| Route | Inhaled | “Inhaled GFF (PT003)” NCT01980615 ↗ |